Advertisement covers the 17th Conference on Retroviruses and Opportunistic Infections

PRO 2000 Microbicide Proves Ineffective

Winter/Spring 2010

The experimental vaginal microbicide PRO 2000, which appeared promising in earlier studies, did not protect women from becoming infected with HIV in a large Phase III clinical trial in Africa, investigators announced in December.


PRO 2000 is a 0.5% microbicidal gel inserted into the vagina prior to sexual intercourse. An earlier study of more than 3,000 African women (HPTN 035) was the first to suggest that a microbicide might help prevent male-to-female sexual transmission of HIV, with a 30% protective effect that fell just short of statistical significance.

But the MDP 301 trial -- the largest microbicide study to date, with more than 9,000 participants -- found no evidence that PRO 2000 reduced women's risk of infection. Over 12-24 months of follow-up, the HIV incidence rate was 4.5 per 100 person-years in the PRO 2000 arm versus 4.3 per 100 person-years in the placebo arm.

Speaking at CROI, Fauci said that studies of non-antiretroviral microbicides like PRO 2000 have produced "failure after failure," and the time has come to move on to next-generation products containing antiretroviral agents such as tenofovir or maraviroc.

Liz Highleyman ( is a freelance medical writer based in San Francisco.

This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. Visit San Francisco AIDS Foundation's Web site to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.